Plexium is a technology-first drug development company. It aims to improve efficiency across the entire drug-development spectrum by leveraging techniques from various physical-science and computational disciplines. In the near term the company aims to enlarge the class of biological targets amenable to small-molecule modulation by recruiting the protein degradation machinery of the cell to targets of interest. Rather than use bi-functional molecules that link target-binders to E3 ligases, the company is developing ‘molecular glues’ that modify E3 ligase substrate-recognition. Plexium is utilizing DNA-encoded libraries to search for molecular-glue degraders in high throughput cell-based assays. The company was founded in 2017 and is headquartered in San Diego, California, US.

Team Member
more about
Joey Mason
Latest News Entry
Plexium Launches with $28 Million in Series A Financing

Funds will help advance Plexium’s DELPhe platform to discover novel E3 ligase-modulating therapeutics to treat cancer and neurodegenerative diseases

all portfolio news